Intrexon Corporation (XON)
Customize your newsletter and portfolio.
Stock Price Variations Over Last 10 Days
Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN‑4001, First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure
Nov 15, 2019